Overview

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effect that CFI-400945 and durvalumab have on breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
AstraZeneca
University Health Network, Toronto
Treatments:
Antibodies, Monoclonal
Durvalumab